Holen Sie sich die Stockscreener-App
129.78
1.57%
2.00
Handel nachbörslich:
129.78
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price - ChartMill
Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Korea Investment CORP Has $10.06 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Trust Advisors LP Has $50.97 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback - Yahoo Finance
Victory Capital Management Inc. Buys 31,981 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - ChartMill
Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada
Barclays Increases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC - MarketBeat
American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today
Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir
Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com
Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today
GW&K Investment Management LLC Sells 17,980 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Segall Bryant & Hamill LLC - MarketBeat
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Strong Buy Ratings and 33.92% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Stock Position Lowered by TD Asset Management Inc - MarketBeat
Rafferty Asset Management LLC Sells 20,445 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risk Check: Why is Neurocrine Biosciences Inc stock going up2025 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
DNB Asset Management AS Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Yahoo Finance UK
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Primecap Management Co. CA - MarketBeat
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C. - MarketBeat
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)? - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Wolfe Research - MarketBeat
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline - Investing.com Australia
Citigroup Inc. Lowers Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Reports Q4 Earnings Miss Amid Strong Sales Growth - Intellectia AI
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential - Investing.com Australia
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - The AI Journal
Neurocrine plans March fireside chats at TD Cowen and Leerink - Stock Titan
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline By Investing.com - Investing.com Canada
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential By Investing.com - Investing.com India
Investment Review: Is Neurocrine Biosciences Inc a strong growth stockWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Wolfe Research Begins Coverage on Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Wolfe Research Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation - Nasdaq
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation After Positive Analyst Views And 2026 Guidance - simplywall.st
Neurocrine (NBIX) Chief Scientific Officer gifts 3,110 company shares - Stock Titan
Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update - Insider Monkey
Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update - Finviz
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
1.53%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):